<SEC-DOCUMENT>0001193125-17-224754.txt : 20170710
<SEC-HEADER>0001193125-17-224754.hdr.sgml : 20170710
<ACCEPTANCE-DATETIME>20170710073632
ACCESSION NUMBER:		0001193125-17-224754
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20170710
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170710
DATE AS OF CHANGE:		20170710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			WY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55364
		FILM NUMBER:		17956372

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-809-2018

	MAIL ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d423913d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;10, 2017 (July 10, 2017) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g423913g09a64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>HELIUS MEDICAL TECHNOLOGIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>WYOMING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-55364</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">36-4787690</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 400, 41 University Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Newtown, Pennsylvania, 18940 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (215) <FONT STYLE="white-space:nowrap">809-2018</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01&nbsp;Regulation FD Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;10, 2017, Helius Medical Technologies, Inc. (the &#147;Company&#148;) posted an updated corporate fact sheet to its website at
http://heliusmedical.com/index.php/investor-relations/overview, which the Company may use from time to time in communications or conferences. A copy of the corporate fact sheet is attached as Exhibit 99.1 to this Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (this &#147;Report&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Report, including Exhibit 99.1 hereto, is
furnished pursuant to Item 7.01 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company&#146;s submission of this Report shall
not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Report and Exhibit 99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward
looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the
Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" align="left"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Fact Sheet, dated July&nbsp;10, 2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>HELIUS MEDICAL TECHNOLOGIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated: July&nbsp;10, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joyce LaViscount</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Joyce LaViscount, Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d423913dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fact Sheet: July 10, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g423913g82q23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developer of the Portable Neuromodulation Stimulator (PoNS&#153;) Therapy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius Medical Technologies is a Newtown, <FONT STYLE="white-space:nowrap">PA-based</FONT> medical device company developing and commercializing the PoNS
Therapy platform, a powerful wearable direct current stimulation technology to treat movement and gait disorders in patients with traumatic brain injury (TBI) and chronic neurological disease. The first targeted application of the PoNS is for
balance disorder tied to mild to moderate TBI. The US neurostimulation device market is forecast to grow to $4&nbsp;billion in 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Features of the
PoNS Therapy platform: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proprietary <FONT STYLE="white-space:nowrap">non-invasive</FONT> wearable platform for treating symptoms of neurological disease or trauma; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Direct impulses delivered to the brain and brainstem via disposable arrays placed on the tongue (razor blade), powered by wearable pulse generator (razor); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The mild to moderate TBI trial with PoNS Therapy was deemed a <FONT STYLE="white-space:nowrap">non-significant</FONT> risk trial by the FDA; we expect to report on results of this trial in early 2H2017;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Class&nbsp;II regulatory process <FONT STYLE="white-space:nowrap">(120-day</FONT> timeline from submission to FDA decision), with expected regulatory clearance in 1H2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pilot studies support motor and gait disturbance correction, across a range of neurological conditions, including Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), and Cerebral Palsy (CP); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reimbursement framework for physical and cognitive therapy portion of treatment in place with commercial and government payers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Protected by over 40 patents including proprietary medical methods (5), as well as design and utility of therapeutic delivery mechanisms (35); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Potential opportunity for human performance improvement applications post medical therapy development. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Highlights: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius is led by an experienced
management team. CEO Phil Deschamps, CFO&nbsp;&amp; COO Joyce LaViscount and CMO Jonathan Sackier each bring over 30+ years of experience in Health Sciences industry with a focus on development and commercialization of healthcare products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is nearing completion of a 120 patient double-blind, randomized, sham -controlled study of the safety and effectiveness of the PoNS device for
cranial nerve noninvasive neuromodulation in subjects with a chronic balance deficit due to mild to moderate TBI. The Company plans to submit for FDA, Health Canada and CE Mark approval and TGA regulatory approval of the PoNS device in 2H 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to over $7&nbsp;million in grants raised by the inventors, the Company has raised over $40&nbsp;million in equity capital since June 2014, and has
received $1.8&nbsp;million in funding from the U.S. Army in support of PoNS clinical development, with a further $1&nbsp;million expected later in 2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in January 2017
establishing a $100&nbsp;million shelf; $9.5&nbsp;million was taken down in the February 2017 registered offering. Helius also completed a private placement financing in June 2017, raising an additional $5.275&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius shares are currently traded on the Toronto Stock Exchange (symbol: HSM) &amp;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Over-The-Counter</FONT></FONT> Bulletin Board in the U.S. (symbol: HSDT) with a goal to be listed on a US national securities exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has received ISO 13485 Certification, which permits submission to Health Canada, CE Mark in Europe and TGA in Australia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Helius Medical&#146;s PoNS&#153; Therapy </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g423913g55x55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Targeted Nerves </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PoNS device delivers specially-patterned electrical stimulation developed to mirror nerve impulses to the brain through
<FONT STYLE="white-space:nowrap">143-gold-plated</FONT> electrodes on the mouthpiece which is placed on the tongue; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stimulation of the brain and
brain-stem via cranial nerve innervation of the tongue is hypothesized to encourage neuroplasticity, or a <FONT STYLE="white-space:nowrap">&#147;re-routing&#148;,</FONT> enabling the damaged brain to compensate for lost function due to trauma or
disease, by recruiting existing working neurons; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PoNS device, when used in combination with specialized physical or cognitive therapy, has been shown
to improve symptoms of patients with chronic neurological symptoms caused by disease or trauma; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Relative to most neurological drug and device treatments,
shorter clinical timelines, fewer study subjects and a shortened regulatory pathway offer relatively lower-cost opportunities to bring new indications to market; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key near-term focus is the ongoing FDA registrational trial for PoNS Therapy for the treatment of balance deficit associated with mild to moderate TBI. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investment Highlights for Helius Medical Technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>One of the few pure-play medical device company in the large and growing neuromodulation market. </B>The neuromodulation market is estimated at nearly
$6&nbsp;billion worldwide by 2020 and is expected to grow in the double digits on a percentage basis annually. Significant industry consolidation by large, diversified medical device companies has left few pure-play companies developing and
commercializing novel therapies. Differentiated technologies like the PoNS&#153; device capture market share relatively quickly post-launch. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Helius
has a number of compelling milestones. </B>The company has a goal to have its shares listed on a US national securities exchange, a critical component in potentially broadening the US institutional investor base. Data from the 120 patient
double-blind, randomized, sham-controlled trial in TBI is expected to read out in early 2H2017. Assuming FDA clearance, the <FONT STYLE="white-space:nowrap">510(k)-de</FONT> Novo to Class&nbsp;II device classification could allow for commercial
launch as early as 1H2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PoNS Therapy could play a unique role in the treatment paradigm for multiple neurological deficits. </B>The unique and <FONT
STYLE="white-space:nowrap">non-invasive</FONT> neuromodulation approach, in conjunction with physical or cognitive therapy, as well as pharmacotherapies, could allow for potential broad applicability across a range of indications beyond TBI.
Positive outcomes with PoNS Therapy could reduce the cost of pharmaceutical and rehabilitation treatments for patients that are incurred with today&#146;s care plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Flexible business model. </B>If the PoNS Therapy is approved for commercialization, the combination of the wearable pulse generator and disposable
mouthpiece could result in a recurring revenue stream. The service model is expected to launch in a clinic setting initially, with potential expansion to a home-based therapy care plan support model, with existing reimbursement for treatment. The de
Novo device classification affords for relatively short clinical trials with a small number of subjects, translating to relatively low cost development to expand into additional indications. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks are discussed
more fully in the &#147;Risk Factors&#148; section of our Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the period ended December&nbsp;31, 2016, which we filed with the SEC on April&nbsp;3, 2017. These risks include the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the Company&#146;s limited operating history; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company being dependent on the ability and expertise of its Chief Executive Officer, Chief Medical Officer and a very limited number of employees; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company having incurred losses since its inception and its anticipation that it will continue to incur substantial net losses for the foreseeable future and may never achieve or sustain profitability;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks relating to the Company requiring additional financing to carry out its plan of operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s independent registered public accounting firm having included an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern in its report on the Company&#146;s audited
financial statements for the year ended December 31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s failure to maintain effective internal controls over financial reporting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the Company raising additional capital by issuing securities or through debt financing or licensing arrangements that may cause dilution to existing shareholders, restrict its operations or require the
Company to relinquish proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks concerning the Company only having one product candidate, which is still in development, and the Company not having obtained clearance from the United States Food and Drug Administration (the
&#147;<B>FDA</B>&#148;), CE Mark, TGA (Australia) or Health Canada with respect thereto; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s dependence on outside scientists and third-party research institutions for its research and development in order to be able to commercialize its product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that if the Company fails to obtain FDA clearance for commercialization of or otherwise fails to ensure that the PoNS&#153; device is available for purchase by the U.S. Government by December&nbsp;31, 2017, the
Company will be subject to significant risk of loss of data and proprietary rights and a US$2,000,000 contract penalty payable to A&amp;B pursuant to the Strategic Agreement with A&amp;B; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the Strategic Agreement with A&amp;B may be terminated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the limited market awareness of the Company and its product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the neuromodulation market being new and growing but undefined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s PoNS&#153; technology being a new &#147;untested&#148; form of neurostimulation therapy and the medical community tending to be very conservative in adopting new therapies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the Company needing to expand its products beyond its single product by commercializing new product candidates, and the Company not being able to do so in a timely fashion and at expected costs, or at
all; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development by others of new or improved devices or products that may result in the Company&#146;s present and future products from becoming obsolete. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This fact sheet contains
forward-looking statements and forward-looking information as such terms are defined under applicable U.S. federal securities and Canadian securities legislation. All statements other than statements of historical fact contained in this fact sheet
constitute forward-looking statements and forward-looking information, including, without limitation, statements containing the words &#147;believe&#148;, &#147;may&#148;, &#147;plan&#148;, &#147;should&#148;, &#147;predict&#148;,
&#147;potential&#148;, &#147;will&#148;, &#147;estimate&#148;, &#147;continue&#148;, &#147;anticipate&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;seek&#148;, &#147;mission&#148;, &#147;goal&#148; and similar words, variations, expressions
or the negative thereof. Forward-looking statements are necessarily based on estimates and assumptions made by management of the Helius Medical Technologies, Inc. (&#147;Helius&#148;, &#147;we&#148; or the &#147;Company&#148;) in light of experience
and perception of historical trends, current conditions and expected future developments, as well as the factors management of the Company believes are appropriate. Forward-looking statements and information in this fact sheet include but are not
limited to statements relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential results of the Company&#146;s ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s estimate of the size of the potential markets for its products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the estimated clinical, regulatory and commercial milestones and the timelines for achieving such milestones; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the therapeutic benefits, effectiveness and safety of the Company&#146;s product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Company will receive, and the timing and costs of obtaining, regulatory clearances in the U.S., Canada, EU and Australia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments and the regulatory environments in which the Company operates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated trends and challenges in the Company&#146;s business and the markets in which it operates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such
statements reflect management of the Company&#146;s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future
results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others, those risks described in &#147;Risk Factors&#148; above and the risks described in our SEC filings, including our
Transition Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the period ended December&nbsp;31, 2016 and our other SEC filings from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This fact sheet speaks as of its date and we, our advisors, and our and their affiliates and representatives undertake no obligation to update, revise or
correct the information contained herein, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry and Market Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This fact sheet contains industry and market data that we obtained from independent industry publications. We have not independently confirmed this data and,
although we believe it is generally reliable, it involves a number of assumptions and limitations, it is inherently imprecise, and you are cautioned not to place undue reliance on it. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g423913g09a64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423913g09a64.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !( )$# 2(  A$! Q$!_\0
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M1D$&NJK]PA.,X\T'='X+6HU*4W3JQ<9+=-6:^044451F%%%% !1110 4444
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MGJMUU1_7F2YY@<?P;.EA:BE*EAW&:ZQ<:5G=;VNM'L^C/@?]HO\ Y.!\<?\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g423913g55x55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423913g55x55.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MI0!%L\8?]!K1O_!3+_\ )- !L\8?]!K1O_!3+_\ )- !L\8?]!K1O_!3+_\
M)- !L\8?]!K1O_!3+_\ )- !L\8?]!K1O_!3+_\ )- !L\8?]!K1O_!3+_\
M)% !L\8?]!K1O_!3+_\ )% ";?&'_0:T;_P4R_\ R10 ;?&'_0:T;_P4R_\
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MP";_ !A_T&-&_P#!3+_\D46 7=XP_P"@QHW_ (*9?_DBBP";O&'_ $&-&_\
M!3+_ /)%%@#?XP_Z#&C?^"F7_P"2*+ &_P 8?]!C1O\ P4R__)%%@#?XP_Z#
M&C?^"F7_ .2*+ &_QA_T&-&_\%,O_P D46 -_C#_ *#&C?\ @IE_^2*+ &_Q
MA_T&-&_\%,O_ ,D46 -_C#_H,:-_X*I?_DBBP!O\8?\ 08T;_P %4O\ \D46
M RM*USQGK,$TUE'I[QQ2F)BRE<L #TS[BO2G1PU*RG>]CDC.K/6-B_YOC_\
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MQ]_SPTW]?\:+83NPO7\@\[Q__P \--_,_P"-%L)W87K^0>=X_P#^>&F_F?\
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M- "4 % "4 % !0 4 % "4 % !0 4 % "4 % !0 4 % !0 4 % !0 4 % !0
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MZE] IB"@ H * "@ S0 E !0 4 % !0 4 % !0 4 &* $H *!A0 4 % !0 4
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M>.,@@9!(]>AI(#U#X*V"-)K&K;-I)6 ?UKLIK0XZCU/5NP_.MS$*GJ,*8@H
M* "@ H 2@ H * "@ H * "@ H * "@ H ,4 )B@84 % !0 4 % !0 4 % !0
M 4 % !0 4",/X=?\@:__ .O^3_T%:[,=\<?1?J<^'^%^IV!KA.D* "@ H *
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MEC<)FD@=3@HZ\@].WTH >/$^F':/-;)0N!L)R <4 2)X@T]XR_FLJXSAD(-
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M0 4 % !0 HZ4 <CX0_Y&7Q3_ -?2_P WKNQ/\*GZ?Y'-1^.99U;_ )'[1?\
ML&WO_HVUKA.DU*8!0 E%P%%(=Q1U]/?TI[(25V<-JUZ;W63@YBA.%'J:X*CN
MSV*"M$NZJZVOAZ[F<@;+=CGTXJDM"*FY\X6\AC=)0< $YX['K5&1H1D21[HM
MRQYPNX<^HJ6ACB0$!P N<[3D9!ZCV%)*S 9),L40;<&/1<$<L/7_ &:?+<+V
M.J^%WA4>)O$SWMZ"UC8$2.AZ/)V ]AUK>$;'+4=SZ 9BW-;7,1*:1%PI[%
M>PI &&]#0 ;3Z&@!<$>M*XA.?\BBX!S_ )%, Q0 G2@ H * "@84#"@5[!0
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M3XD#J!C(QD@\8-423*A3[C$']*!DJR$G#=?:@!_XYH * "@!: $H * "@04
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MQ2#&#2&<K=: RN6M7#+_ ,\WZB@#+FM;BW)\V)T_V@,T"*W!Z'F@!,NIX;%
M#3+(/XLT7&&]NI4?2IN4(;@#Y3"/J.,4#);>Y\J4O%))&^/O(>?I33%8E9L0
M&$SMY;'<R$\$^M.X6*\MLI4LCT T4V4CM5$V&C^$=#2$>B>']#MY_AY<ZA=O
M*J1[Y$,3[<,.F:VB]#!KWA_PL8LVJ.WWB%Y[UPU]3U,,['HI!MI4ND&Z)AAP
M.QKF2L=W,SK=%F5T61V55]S6RE8YJB;-._\ [/N;>2TED26WN5,4B#GKQG\*
MT4S#E:1\\>&]"O\ 0/BE-I\3M&=/=G\W&?E_A_.MXNYRR6I[=9Z[>J/WJQR\
M]2N#]*OEZDFDNNJ5_>0;3[4 6H=4MI"!N(/O4@7T=6&5.1ZB@8^@ H * "@
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M5(6)X5^4'^+WKL3NCB:LQ^<#.,>]2!/&RI'YLG"= ^.#4@7+.^$,H\M]T?\
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MI51CIQ5Q=SGE%IGFL$[6NI/;.Y/ER%>35M6':QZ)8OYEA$Q]*1-RQ0,* "@
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M;R)>V8BN4# X.1ZUK"5CEJPU.F1E:*/8<H% %=497//G"S'46$G;0*8!0 4
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M[!9H8525<,O!]ZI*Q$W<W;"Z6-Q'G*-^AK>+L<TXFIP.!6Z9R25F)0(* "@
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M:W2.!O6YK^$?%%MXMT)-0C'E7,?[N[@/6-QUR*=PW-O&!TS_ "- K"T#V$H
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MZTQG7:'KMCXCT>'5--??#*<%#UC;NI':@#1/ _D.] "4 %  : $I@% !0 4
M% !0(6@ _AQVI%=#)USP[9:\FZ9G@N@,)<1\,/8^HIV).,_X0_7M)N"4"7EH
M.2T9P<>N*4E=&E.5I'-ZG:FWN&(!P>0#P<5R2C8].G.Y#8SLCY/S.?7M6#T.
M@[32+I7C*N<MCOZ>E6MC">AQ'C/35TO4A<P@_9YO3HIIETV8R7XC7E\8H02W
M*4MU/J0,,;%8NYJB2U9Z7'$D4$*9=SD^YH$=%%I,FGJ'LW_>X_> ]_:@DF6:
MWG<17,?E-[],U(P_LYH+C<I(7^$CI2&=#I?F* ",X^]V(H0FSJ(.(U*D'-:H
MQ;&:IN2Q#*P!W=:&.)':L''+ ^M)%MZ&E;OY<RL._%:Q9RU$:W<^U;G*% !0
M M !0 N*!'+^ K^WM=,OHI9 C-?.1GO\J\?I79COCCZ+]3GP_P +]3JUUC3R
M0!>1<G YZFN$Z1@US3"NX7L6WW- $B:I920-,EU&T:=6!Z=OYT ,_MK3MH)O
M8@#DY+8Z4  UK3@VTWD? SR?UH 5]8T^.1HS=IO7&1GI_D4 3M=P*@<S+M(R
M#N'(^E*P(HW43ZA"[R@Q0H"5P<.W'Z4%1W.2CMYAI\I2<[0Q^^-U"1W[)$.C
MPW(:23;%)SP<E?Z&G:PY2&ZQ>RNWE^02PZA2#G^5"9I!:":<[06QE^QR@CU*
M_P"-5:Y%]2WI5K<ZB\LQ@9-O0LP 'Y9K.2L959V1TLLBVUNOG/@XP2!R3["H
MLSE3N9DR2W7,H,<!_P"68^\?J:5K&\"C=(JIL5< #  J>;4W2.5N'6TN'1F^
M5^0!_A5VNBXLHR&24_\ /-/?J:CENS9:D+B.!.PS^9HV&VK%8K,3YD8V8XVG
MO6BD<TH.]T/A)=E5E*-TYZ4.-P=;^;0Z:PT:"18P<AAU:-L54:9RSKI?#J=!
M::#:*5:0/,?^FCDUIR')+$S?0VH+>*%<1QJ@'H,57(9.?-N9\TGGZM%Y$32+
M #EU'R@GMFM(JR.>44VK&I%;[06E(:0\GV^E1=&CA%;F3XGC#Z>N/[U<6(M8
M]G <BDK'(K;^U>:T>\ID@@-)(3F8L<$D$LA,K)$LA3=U"'MD'M6[LS\_P\*^
M#JSM5E&"DXW6JB^ET]+-/?2QL102J@\PJS>JC'%9-+H?;X9UHT[5I*3[I6'^
M3Z\"CE.CGZ%*[=F.Q>@]*M3L1*GS&KH ?SO*90!U!%6I<QPUJ:AJ=2(W4<'\
MJ>QQ.2&--)%S2O8M)-#H-3CS][:XK:$KF4J;1TUM()K=''\0S77$YI*Q,.E4
M(* #O0 HH Y'PA_R,OBG_KZ7^;UW8G^%3]/\CFH_',R_B#'YGBK0 .UG>'_Q
M^VKS:FQZ6&^/Y&'/(8;J,*.U8'>),B B0=^M(5A&^4 =CUIDL:Z+*LL)7(="
MM%P1C:%;MY(B SY;%#GMBFM="KI;G3:5H$UW>L(Q^ZZE^PK109RU*B6QW5G9
M06%N(+=<#JS=R:WBK'(Y7+%4["T"L[ Q02OS+]X#OVJB3SW6M*OO!&LS>)_#
M=L9=-F/_ !,].7L.\B#UH&=II.K6&NZ;%J.F3":VD7Y?[R-Z,.U %S(QF@ Z
M<4 % "4P"@ H * "@ H$+0 4#"F/0 2O*G;2W%Z')^+_  \EY"U];IAT_P!8
M!W]ZQG$Z*55)V9YU,@@? '..M<S1ZD7=%W3[XQ%26XS0M :NB'Q+>PW&G31S
M'Y#R/KVQ3(2L>?\ ]G73PB1I<@\A.XH$W<GMYHX(0G(]:"6=EX?LS]B2^D&&
MD^X#V%%B;E^5V!!!SZB@".*9&?9,@9#V8=/I2&:4=KL'[ES)">J'J/I2&;-D
M VTKRP[_ .--$LWH!^[  &16J9BQ+V#SK*2(=>HH9479%&T38-N,#UJ"KFB.
M ,=JTAN93V-K^ 'V%=)Q"T +0 4  ZT /H$<QX#M(;O1;X31APNH2$>H.U:[
M,=\<?1?J<^'^%^ITYT73F=&-I&6C.4/H:X3I&2:%I<@ :SC;&!T]* )X].M(
MXC%' JH?X1]<T 5YM!TN?'F64;<$<]LT ,A\/Z="DB^5Y@D #%SG ':@":/1
MK")G*6R OC)Y.>,"@"RMK H7$,?R@ ?*,C% ^A'J2R-I\RQ*6=AC I#@]3B[
MTR66EM%(A1CU!H/0A)6%TAO+TTN>F*!Z,S.;FZR/6F;I)(T;QA';Q(O5C1<Y
MYNQT5IBWM8[>UC\R4C+#/"^Y/]*DX9LF6Q ?S96,LY_B/0?04$IE6Z"QJS.P
M1!R23@5FS>$C"N3-<?ZA=D?_ #T8<_@*F]CI3T.6UR!+(1W())4_.[=<5M!7
M1:*LD@E.;<;DQG>>E9N+3-D0&!4.XDNQ[FLV%AGS%L#DU2"UB_;V3"X19%![
MXK:G%F%2,9&FGEPG*HT?/&QR#7;%6.">&OL;6GW :54-]/&QZ!P&%-HY94)(
MW%LI9/\ 77;.G]U5"Y_*LWH9^S:*^M_;-/T22720B/#\Q0KG*]_Q[_A6%1R2
MO$YL5*K3I.='=&-IVK:E>-%%<ZK':3R@,B26@VR#_9;=@UDIR:U?X'#1KUJK
M49S46^\=_1WU-'69?M#K;K]Q.OUKGJNY]?AH\FIEK:>U<_*=WM!XM,=J.47M
M"(:7&&F)7(FQO4].F*+,Y50I*51O7GW73:Q12)M,G6VG)-LYQ#(?X3_=/]*=
MKGGT:TLOFJ%1WIOX7V_NO]&6YXE4;>I] .:7*>VJJ1!'I=Q)(I6W8 ]V%-0"
M6(LCH].TH6B;B '[U25CAJU><T2H JSF*%Y*%&W%9M'1!V*MAHTM_+Y@;RX@
M>36M*)%21VD$2P0)&O11BNNUCEW)>E4(*  T *.E '(^$/\ D9?%/_7TO\WK
MNQ/\*GZ?Y'-1^.9F>/WV>+/#YSC_ $.\_P#0[>O,JZ(]'#_$8,WSW&[VXKGN
M=VHQ3YF%'53TH"[)?+,EQCH!5I VD2P6%U<3?Z/ TA!Z=*KD,G42.AT7PG'8
MAY+P[I'8ML7M]:TC"S,9U4T=$D:1)Y<2A$_NK6IRRE<=3$@I % !0  GJ/HP
M]O>@#B-2\)7^BZE)KG@QE@FE.;K36/[JX'<KZ-0!L^'/%EAXE5XHU:TU*#B:
MQEX=2.N/44 ;O4]OIZ4 )0 M, H * "@ H * "@ H * #\*:&@&,88 @]142
MU)6]SS#Q5I'V'4'"C]TWS1US21ZE*>ECB[FX%IDDGD\ =ZS.A,ILDUPZS7I/
M'W8O2F2V#D!>.#VIDE%;(ZAJ-O:J/GE<*V/2@3/2YXDAVPQC"Q+M IF9E7+!
M>1P:0R.*7. R@BD,VK(J&#1-C':D,W;6-7"G_52>W0TT2S8@!Q@CYZM&;)3T
M(/XTR45_* ;(Z5)9+&NYPM7'<SF]#:"XX]!72<@M A0*  "@!<4 . H$<]\.
M_P#D#ZA_U_R?^@K79COCCZ+]3GP_POU.OKA.D* #I0 9% '.KXEG2 2W.ES1
MAB^T+@[MIQF@!TGB=8W"FQF*[5((YZ]CQQ0!+-KQ@@M9FT^9O/5FP@R5P0,'
M\Z!,BB\2B6&25=/N1'$2&++@\'L._6F"T$BUJWOFGCETV8&)"^)8\ X[<T%<
M[11O+M!%)&ND,RJH8^6< J<8(_,_E06JK18TS3+"3SB+619(S@J6R:3*]O(L
M-H45W,I>!H8EZ9.6/T]*D3J-FS%!';0A$4(B_P">:HR>I6>X:;*6L?F>KMPH
M_'O2$5&T\&023,TTHZ$]!]!4-%Q=BA>%5?RT4RR_W%[?X5-C:,SF]7TI[V2.
MWG(;)W%%^[CT-;PLD;PD8W]GRZ=N@=2;;),;X^Z/0UE-W>AT*1#)!GD<CL16
M+3-4QD%L/M"9X .<FM(1=R)LT+>&26_E:$$INX<G@?2O1C%(Y;%R6VEEN$CA
M8;D.7;L.*IZ"V+"V"H=WS%O7UIZ6(DSI]&9I;0JQY3@5A)G',TS'\N"*S1G:
MZ,%M'M[33)[&95N+9I"T,;K_ *H'G /L<\^]<\DDK&6'P,.1TIJ\;Z+L8_V#
M4=.^:WS>6XZPN?WB_P"ZW?Z&N9FG)B<'_"?/#L]UZ/KZ,O:?<VM^&$+8D3[\
M3C:Z?44'50QM/$+W'JMT]&OD: MA18Z.<=]C/]WBE87.5[_2FN;-H/*5U?@@
M^E58SJQA6@Z<U=,IZ7$='O5T[4%#/+_Q[7!Z/_LG_:'ZT;'FTJ\\/-8>J[K[
M+[^3\_S.@,>*1Z',V,9BHXI#L027")DL<4[FL8F9+*+F=0E)*[*>B.ML8!!:
M(HX.,UUPC8Y)2N6ZT9*"@ H 0T .'2@#D?"'_(R^*?\ KZ7^;UW8G^%3]/\
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MBD8XK9:&4YI[%@6Q%7<R#[-Q2N.Y,B!(P*5Q#6Z5#!(K%!FLFA@$ I6$+C'
MI6 :>.](9C7.A*D[7>E3FQNCRVT9CD_WEZ?B.:DX:F"2E[2@^67X/U0V#7FM
MI5MM9@%G,3A90<PR?1NWT-%R8XMPER8A<K[]'\_\S:##;D'BJ/0L9^J:?%J=
MMY3DI(IW1R+PT;#H129E7P\:\.5Z/H^S*.FZA))(]A?@)?PCG'W95[.O^>*D
MRPV(DW[&MI-?BNZ+<V%!S4M'J0*2\R@CDU*T9<GH=/IN[[+AJ[8''+4N5JS-
M:!04% !0 HZ4 <CX0_Y&7Q3_ -?2_P WKNQ/\*GZ?Y'-1^.99U?_ )'W1?\
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M6@!0,4 .H <* % H XGPA<W=KH-ZUI#YC-J,@8XSM&U><5V8[XX^B_4Y\/\
M"_4V?[:UB-E TIG0QA@,$$G)R/Y5PG2 U_5N^BN,Y'?B@!%U[5I[AH(M+PZD
M9+!@!D_>^GM0!,FM:M)=+!_93*-I^<YV@@X'Y]: $37-3D65TTP;(B0V6/S8
M]*0$4/B._G<B+36E09^= V,XZ?A3 FM=8U2>UN)#IC1R)M"(V0&)/)H 0:SJ
M[7 @&D,&W8W-G;]<^E #_P"U]4%['"^DN(B^TR+DCZ^W_P!:@3$N]5U6.ZF2
MULA*B%@/E)R1C _4T"+=A>WES$PEA43*H)!!4 GM0,L?8WG.^[<,!TC0_+^/
MK0,G>6.W3=(0B@=_Z4 0^;<7'^I7RHC_ !OU/T% $D%I' 2ZY,AZNW+&@"QB
M@ H * &[:0$7E#S,TK!<GZ50!0 4"(V-("(FI"]B(C%0] &E@.]9-E)$;2J*
M5Q\I&TX]:FY7*,,P]: Y1DBPW,313(LD;#!5AD&F3*DIQY9*Z,@Z?>Z4=VCS
M>9;][.=N!_N-_#]#Q5)6V//^JUL-KAW=?RO]'T_(MV&LVU[(8&W6]VOWH)AM
M8?3U'N*I-,WH8J%5\CTEV>__  1FLV45Y"CI)Y5W"=T,PZH?Z@]Q2DD:8C"^
MW2:=I+9]O^!W,NWU9[U6@E3RKN+B1!T^H]C639I@\1[1.$U:<=U^J\F:UA;L
M6!(YHC&[.F<CIH4\N)0*[8JQS7):LFP4AA0 AH <.E '(^$/^1E\4_\ 7TO\
MWKNQ/\*GZ?Y'-1^.99U?_D?=%_[!M[_Z-M:X3I-.F 9H 2@ H * "@ H 2@
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M_,=T?_P42_\ R32&']G>+O\ H.Z-_P""B7_Y)H /[.\7?]!W1O\ P42__)-
M!_9WB[_H.Z-_X*)?_DF@ _L[Q=_T'=&_\%$O_P DT ']G>+O^@[HW_@HE_\
MDF@#%M_ VN6D$T-MXE:".9F=Q#$4Y(P2/FR/SKT98NE.W-"YRJC..TBW_P (
MQXH_Z&R3_OU_]>I^L4/^?8_95/Y@_P"$8\4?]#9)_P!^O_KT?6*'_/L/95/Y
M@_X1CQ1_T-DG_?K_ .O1]8H?\^P]E4_F#_A&/%'_ $-DG_?K_P"O1]8H?\^P
M]E4_F#_A&/%'_0V2?]^O_KT?6*'_ #[#V53^8/\ A&/%'_0V2?\ ?K_Z]'UB
MA_S[#V53^8/^$8\4?]#9)_WZ_P#KT?6*'_/L/95/Y@_X1CQ1_P!#9)_WZ_\
MKT?6*'_/L/95/Y@_X1CQ1_T-DG_?K_Z]'UBA_P ^P]E4_F#_ (1CQ1_T-DG_
M 'Z_^O1]8H?\^P]E4_F#_A&/%'_0V2?]^O\ Z]'UBA_S[#V53^8/^$8\4?\
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6<C.>_O66(KQJJ*BK6+I4W"[;O<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g423913g82q23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423913g82q23.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !( )$# 2(  A$! Q$!_\0
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M1D$&NJK]PA.,X\T'='X+6HU*4W3JQ<9+=-6:^044451F%%%% !1110 4444
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MGJMUU1_7F2YY@<?P;.EA:BE*EAW&:ZQ<:5G=;VNM'L^C/@?]HO\ Y.!\<?\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
